Tag: Benralizumab

1. Two complementary phase 3 clinical trials randomized patients with moderate-to-severe COPD to receive either benralizumab or a placebo and found that the trial agent did not lead to a significant reduction in chronic obstructive pulmonary disease (COPD) exacerbation rates. 2. Safety outcomes were comparable between groups. Evidence Rating Level:...
1. Use of the interleukin-5 receptor antibody benralizumab lowered oral glucocorticoid use while maintaining symptomatic control in patients with severe asthma on chronic oral glucocorticoids. 2. Lung function as measured by forced expiratory volume in 1 second (FEV1) and asthma symptoms were similar for patients treated with benralizumab or placebo...
1. Patients treated with benralizumab did not experience a reduced annual rate of acute COPD exacerbations. 2. However, benralizumab treatment conferred clinically significant improvement in lung function as shown by increased pre- and post-bronchodilator FEV1. Evidence Rating Level: 1 (Excellent) Study Rundown: Chronic obstructive pulmonary disease (COPD) is a...